Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) @ 06/10/2021

RTSL Revolutionizes CBD Vaping Industry with Convenient, Safe, and Economical FDA Listed CBD Inhaler Device.

Company Summary:

Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) is an SEC fully-reporting, growth-oriented manufacturing and marketing company focused on employing FDA-approved Metered Dose Inhaler (MDI) technology to deliver aerosolized cannabinoids, such as CBD and CBG.

Key Metrics @ 06/10/2021

Closing Price $0.57
52 Week Range $0.21 to $2.00
Shares Outstanding 193.379M
Shares in the Float 30.856M
% Held by Insiders 89.89%
Shares Authorized 650M
Average Daily Volume: 30 Day 7.729
Market Cap $92.822M
Reporting Status SEC Reporting
Financials Audited
Most Recent Filing: 10-Q  for 03/31/21 Filed:  05/14/2021
Fiscal Year-end 12/31

(Source: OTC Markets, Yahoo Finance, SEC filings)

Unique Delivery Mechanism:  Properly formulated MDI deliver Active Pharmaceutical Ingredients (API) (drugs, nutraceuticals or bioceuticals) through the pulmonary tract. An MDI is generally the most efficient delivery method for an API other than an IV.

 

RxoidTM Metered Dose Inhaler (MDI)

Corporate News and Market Drivers

Rapid Therapeutic Finalizes Lab Work on Pharmaceutical Formulas

DALLAS, June 10, 2021 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC Pink: RTSL), an SEC fully-reporting, growth-oriented aerosol manufacturing company focused on delivery of non-psychoactive cannabinoid compounds, announced today that it has concluded lab development on three (3) formulas related to manufacturing of pharmaceutical grade isolates used in both metered dose inhalers and other aerosol products.

RTSL has developed three (3) proprietary pharmaceutical formulas, two (2) for cannabidiol (CBD) and one (1) for cannabigerol (CBG), to initially be used in Metered Dose Inhalers (MDI). One CBD formula is expected to be used in testing of the MDI which the Company plans to submit to the U.S. Food and Drug Administration (FDA) in connection with an Investigational New Drug Application (IND), as previously announced. The other two are planned to be used in RTSL’s other products.

RTSL’s CEO, Donal R. Schmidt, Jr. stated, “We initially set out to find an ultra-pure, unadulterated pharmaceutical grade CBD isolate to use in our MDI. Early on we learned the purity level of an isolate is materially related to airway irritation and the level of cough reflex when using an MDI. We also learned CBD isolate is not chemically compatible with metered dose inhalers without significant modifications in the manufacturing process. In short, we were unsatisfied with any product we could source in the hemp space to meet our needs. As such, we set out to engineer a quality isolate to meet our needs.”

“With the purchase of Razor Jacket and the addition of Dr. Drinkwine, each as previously announced, we learned how to manufacture pharmaceutical grade isolate in-house. We believe our process is unique and will result in one or more patents being granted to RTSL. Once the patent applications have been filed, which are planned to be filed in the next few weeks, we expect to release the…

Click on above link for full press release.

 

Rapid Therapeutic Prepares to file Investigational New Drug Application for its CBD Metered Dose Inhaler with FDA

DALLAS, June 02, 2021 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC Pink: RTSL) an SEC fully-reporting, growth-oriented aerosol manufacturing company focused on delivery of non-psychoactive cannabinoid compounds, announced today it has executed two (2) contracts to conduct Phase 1 human clinical trials of its flagship metered dose inhaler (MDI) containing Cannabidiol (CBD). RTSL entered into these two contracts in preparation for filing an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA).

Filing is anticipated in the next 30 days. An IND is a request for the FDA’s authorization to administer an investigational drug to humans and is the first step towards designing and conducting clinical trials in the U.S.

RTSL engaged Dr. Charles Powell, MD who is the Chief Medical Officer (CMO) and founder of a primary care group in North Texas with over 90,000 patients from which volunteers will be solicited for the planned studies. Dr. Powell is responsible for oversight of the studies on behalf of RTSL.

Dr. Powell in conjunction with Dr. Haresh Boghara, MD of Epic Medical Research, who has been engaged as RTSL’s primary medical investigator, will launch five clinical studies to assess RTSL’s MDI containing CBD for dosage, efficacy and safety. The planned studies will initially focus on therapeutic benefits of CBD relating to depression, anxiety, insomnia, ADHD and arthritis/chronic pain. Of importance, the studies will measure blood serum levels (pharmacokinetics) to support clinical observations. RTSL will need to file and obtain approval of the IND by the FDA to begin the planned studies.

Dr. Powell stated, “Based upon my observation from our clinical experience…

 Click on above link for full press release.

·   Rapid Therapeutic Hires Pharmaceutical Industry Authority to Oversee Labs

DALLAS, Jan. 26, 2021 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC Pink: RTSL) an SEC fully-reporting, growth-oriented aerosol manufacturing company focused on employing Metered Dose Inhaler (MDI) technology to deliver non-psychoactive cannabinoid compounds, announced today that it has hired Dr. Duane Drinkwine, Ph.D., to oversee all laboratory operations for the Company.

Dr. Drinkwine comes to RTSL with 30+ years of experience in the pharmaceutical industry. He has significant experience in isolate crystallization. For the last 5 years he worked as a consulting engineer for multiple laboratory equipment manufacturers in both “Big Pharma” and the hemp industry. For 10+years he worked for GlaxoSmithKline as a Laboratory Reactor Scientist in the process safety group and scale up chemistry.

RTSL’s CEO, Donal R. Schmidt, Jr. states, “Dr. Drinkwine was instrumental in development of our proprietary intellectual property wherein a pharmaceutical grade cannabinoid isolate was perfected. Dr. Drinkwine was the person who built Razor Jacket, LLC’s lab and processes, and the deciding reason we purchased such assets. We believe that his knowledge about isolate production of prescription Active Pharmaceutical Ingredients (API) in the pharmaceutical industry world gives us an advantage in several areas, least of all, safety, and ultimately Food and Drug Administration (FDA) interaction.

He is reviewing all our formulations for safety and purity. It is critical that our MDI not cause any adverse events such as a laryngospasm or bronchospasm. In addition to formulations, he will be responsible for oversight related to Current Good Manufacturing Practice (cGMP), and Occupational Safety and Health Administration (OSHA) and United States Environmental Protection Agency (EPA) regulations.

Click on above link for full press release.

DALLAS, Dec. 03, 2020 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented aerosol manufacturing and marketing company focused on employing FDA-approved Metered Dose Inhaler (MDI) technology to deliver cannabinoid compounds, such as CBD, CBG, and CBN, announced today that it has selected Accent Clinical Research Professionals, LLC (”ACCENT”) of Allen, Texas to administer RTSL’ first round of human research of its proprietary CBD and CBG blended MDI. RTSL expects to sign the formal agreement by December 31, 2020.

ACCENT is a clinical research center, specializing in Phase I-IV pharmaceutical and device studies dedicated to providing high quality and reliable research data to sponsors striving to advance today’s medicine while rigorously maintain the safety of patients. The principal investigator of the MDI for the clinical trials is Dr. Neal C. Lawrence, M.D. and Dr. Charles L. Powell, M.D. will be the medical advisor to RTSL.

RTSL’s CEO, Donal R. Schmidt, Jr. states, “Our decision to go with Accent (www.amrprofessionals.com) and the two physicians we chose was quite simple. Accent is known for quality and integrity which has made them a preferred …

Click on above link for full press release.

·        Rapid Therapeutic Completes $14 Million Acquisition of Razor Jacket

Razor Jacket is an Isolate Lab capable of producing up to 250 kilograms per month of 99.9% pure medical grade isolate

DALLAS, Dec. 01, 2020 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented aerosol manufacturing and marketing company focused on employing FDA-approved Metered Dose Inhaler (MDI) technology to deliver cannabinoid compounds, such as CBD, CBG, and CBN, announced today that it has closed on a transaction acquiring all of the assets of Razor Jacket, LLC based in Hillsboro, Oregon.

The transaction is valued at $14 million in cash and stock which includes all potential future earnouts of $13.2 Million.

An “isolate” is the ultra-pure form of any single cannabinoid, having no other chemical ingredients. This vertical acquisition assures RTSL the ability to manufacture “in house” any combination of CBD, CBG, CBN and/or terpenes up to a total of 250 kilograms a month of 99.9% pure isolate.

Any isolate not consumed in RTSL’ primary products will be marketed as medical or pharmaceutical grade isolate directly to the health and wellness space. The new lab being relocated to North Texas assures RTSL can make more than 3,000,000 MDI units annually without outsourcing. Further, the acquisition will reduce RTSL’s cost of goods sold by approximately 50% per MDI unit.

RTSL’s CEO, Donal R. Schmidt, Jr. states, “this acquisition does a lot for our growing company.

Click on above link for full press release.

Key Investment Highlights:

  • In 2019, vaping represented between 22% to 30% of the consumer market for CBD – (approximately $5B); total CBD market could be $23.6B by 2025
  • Pressurized Metered Dose Inhaler technology is FDA-listed, convenient, precise, safe – and largely obsolesces vaping
  • State of the art lab tested to ISO 6 standards and FDA Good Manufacturing Practices (GMP) related to ISO 13485 will allow RTSL to pursue FDA registration for all of its product
  • RTSL has the technology, marketing and management team to be a “key market leader” in CBD delivery systems

Bottom Line:

Interested investors should definitely keep RTSL on their radar screens or even consider building a position in the shares at what looks like a very reasonable entry point.

Posted By Research and Editorial Staff – MicroCap MarketPlace

_________________________________________________________________________

More About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)… courtesy of GreenLeaf Investing Newsletter

RTSL has developed and perfected a new method of formulating and manufacturing pressurized metered dose inhalers (pMDIs) that contain and properly aerosolize proprietary formulae consisting of one or more cannabinoid compounds, such as CBD, CBG, and/or THC (only sold where legal).  The Company’s RxoidTM product line is manufactured in compliance with cGMP, on FDA approved equipment. Note that while non-THC Cannabinoids such as CBD and CBG are not yet approved by the FDA, under the laws of Texas and of many other states, it is legal to consume, sell and export them to legal jurisdictions.

Properly formulated MDIs deliver Active Pharmaceutical Ingredients (API) (drugs, nutraceuticals or bioceuticals) through the pulmonary tract. An MDI is the most efficient delivery method for an API other than an IV. In addition, MDIs are less expensive than any other route of delivery, based on the net cost per bioactive mg as tested in blood serum levels. MDIs are, however, expensive to formulate and difficult to manufacture in order to deliver cannabinoid compounds to the level required by the FDA and FTC truth in labelling laws.  Ideally, a properly formulated, properly manufactured MDI containing cannabinoids will deliver exactly the same dose on its first use as well as its 100th use.

RTSL markets its RxoidTM MDI products directly to pharmacies and physicians who treat GAD, PTSD and other stress and anxiety disorders.  RTSL’s MDI products also can be purchased by consumers online, at www.rxoid.com.

Interested investors can find out more about Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) on the Company’s website at www.rtslco.com,

Contact:
Donal (Don) R. Schmidt, Jr.
Chairman and CEO
[email protected]

Phone: 800-497-6059

Fax: 877-676-8527

www.rtslco.com

__________________________________________________________________________

Disclaimer and Disclosures: Green Leaf Investing, Green Leaf or GLI is a financial publisher and not a FINRA broker/dealer or investment adviser. Green Leaf is not registered with the SEC / U.S. Securities and Exchange Commission or any state securities regulatory agency. Readers, subscribers and web site visitors are responsible for individual investment decisions. All information contained in our newsletters or on our web site and in our blogs should be independently verified with the featured companies and readers should always conduct their own research and due diligence and engage professional investment advisers as they deem appropriate before making investment decisions. Please review the Terms and Conditions of Use, including without limitation all disclaimers of warranties and limitations on liability contained therein. Your use of any information on our websites, contained herein or in our newsletters and blogs constitutes your agreement of same. GLI did not receive any compensation for this article. However, officers, employees and affiliates may hold positions in the featured securities discussed in our newsletters or on our web site and blogs and may buy or sell said securities at any time without further notice. GLI and/or affiliates may from time to time receive cash and/or equity compensation from featured companies for corporate communications services. In the interest of full disclosure, Mike Casson, GLI’s Executive Editor is also president of Casson Communications, LLC (CCLLC) and Founder/Executive Editor of MicroCap MarketPlace, affiliated companies. CCLLC has received thirty-two thousand two hundred fifty dollars in cash compensation and fifty-thousand shares of restricted common stock from the subject company for corporate communication services and allocated a portion of that compensation for the distribution of this article as part of said services. You should be aware of these potential conflicts of interest. We believe the information contained herein and in our publications to be reliable but cannot guarantee its accuracy; therefore, all information is provided as is without warranty of any kind. Past results are not necessarily indicative of future performance.

SOURCE

Research and Editorial Staff

GreenLeafInvesting.org

© 2020 Green Leaf Investing, All Rights Reserved